Plan: OPEN | Option: Growth | Sailesh Raj Bhan

22 Sep 20 | 12:00 AM

226.35 1.38 (0.61%)

  • Outperforms

    57.16%

    Return (1Y)

    beaten by 4.84%

  • Less Volatile

    1.56%

    Standard Deviation (1Y)

    Lower than by -0.39%

  • Not so consistent

    6/12

    Months

    Has beaten

  • Value research rating

    Not Rated

Scheme Trivia

  • Reliance Pharma Fund (G) fund has been the 5th best in 5Y performance in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been given the 5th best Risk adjusted performance for the past 5Y in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been the 5th best in the 5Y SIP performance in the Equity - Pharma category

Critical Parameters

Everyone of us wants to create wealth by investing in top funds. Have a look at the key parameters that you need to check before deciding to invest in a mutual fund.

Returns

In last 1 year Nippon India Pharma Fund (G), has beaten its benchmark, by 4.84% (CAGR difference)

57.16%

Outperforms

This is +ve Alpha

Performance Chart for Rs

Invested in

Risk

In last 1 year , the volatility of Nippon India Pharma Fund (G),is Lower than its benchmark, by -0.39%

1.56%

Less Volatile

Risk Meter

Peer Comparison on Risk - Return

Consistency

For 6 out of Last 12 Months, i.e 50% of the times It has beaten its benchmark,

Consistency Meter

Outperforming Stocks Vs. Underperforming Stocks

Based on the last 1year analysis, currently there are, 20 Stocks beating the benchmark 0 Stocks not beating the benchmark

View Stock Composition